CoChat

Survival after adjuvant 5‐FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer

de Vos tot Nederveen Cappel, Wouter H., Meulenbeld, Hielke J., Kleibeuker, Jan H., Nagengast, Fokko M., Menko, Fred H., Griffioen, Gerrit, Cats, Annemiek, Morreau, Hans, Gelderblom, Hans, Vasen, Hans F.A. · 2004 · International Journal of Cancer
Cited by 118

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

In vitro studies suggest that a deficient mismatch repair (MMR) system reduces 5‐Fluorouracil cytotoxicity. Colon cancer (CC) in hereditary nonpolyposis colorectal cancer (HNPCC) is due to a dysfunctioning MMR gene that leads to microsatellite instability (MSI). Clinical studies on the efficacy of 5‐Fluorouracil (5‐FU) in MSI high tumours are contradictory. In a retrospective study, we compared the survival of subjects with stage III CC from HNPCC families that were treated with and without adjuvant 5‐FU. The Dutch HNPCC family registry was used. Information on adjuvant chemotherapy for stage III CC was obtained from subjects of families with a mutation and/or who fulfilled the AMS criteria or who were strongly suspicious for HNPCC. CC specific survival was calculated. Observation time was measured either until the date of death, date of a second primary CC or until the closing date of the study, i.e., June 1, 2001. Statistical analysis was done by Kaplan‐Meier survival analysis. A total of 92 subjects with stage III CC were included. Twenty‐eight of them (17 males) had adjuvant treatment with 5‐FU. The median follow‐up was 4 (range: 1–17) years; 8 subjects died of CC. The 5‐year survival was 70% (95% Cl: 49–90). Sixty‐four subjects (36 males) did not have adjuvant therapy. Their median follow‐up was 6 (range: 0–23) years. Twenty of them died of CC. The 5‐year survival in this group was also 70% (95% Cl: 59–83). To date, the selection of patients with CC for 5‐FU treatment is based on the stage rather than the biology of the tumour. In our study, the 5‐year survival of subjects treated with and without adjuvant 5‐FU did not differ. Further studies are necessary to elucidate the role of MSI in 5‐FU treatment of MSI‐H tumours in HNPCC. © 2004 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.11712

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 118

Metadata

Authors
de Vos tot Nederveen Cappel, W. H., Meulenbeld, H. J., Kleibeuker, J. H., Nagengast, F. M., Menko, F. H., Griffioen, G., Cats, A., Morreau, H., Gelderblom, H., & Vasen, H. F. A.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2004-01-09
Volume
109
Issue
3
Pages
468-471
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2009052175
Cited by
118
References
2
FWCI
8.24
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Survival after adjuvant 5‐FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. https://app.cochat.ai/papers/10.1002/ijc.11712
The paper
de Vos tot Nederveen Cappel, W. H., Meulenbeld, H. J., Kleibeuker, J. H., Nagengast, F. M., Menko, F. H., Griffioen, G., Cats, A., Morreau, H., Gelderblom, H., & Vasen, H. F. A. (2004). Survival after adjuvant 5‐FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.11712

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.